Press release
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.\n\n\n“I’m thrilled that United Therapeutics continues to report double-digit revenue growth and our highest quarterly revenue ever,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer. “We expect this growth trajectory to continue with our current business as we expect to reach a $4 billion annual revenue run rate by mid-decade. Beyond that we expect continued waves of growth with an additional doubling of our revenue from the potential launch of Tyvaso in pulmonary fibrosis and ralinepag in pulmonary arterial hypertension, and then yet another doubling of our revenue with the potential for an unlimited supply of tolerable, transplantable organs in the next decade.”\n\n\n“Tyvaso and Orenitram continue to drive our revenue performance with record revenues and the highest number of patients on both therapies,” said Michael Benkowitz, President and Chief Operating Officer. “Feedback on Tyvaso DPI has been overwhelmingly positive, and its convenience and ease of use have revolutionized the way patients with pulmonary hypertension manage their disease.”\n\n\n\n\nSecond Quarter 2023 Financial Results\n\n\n\n\n\n\n\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\n\nThree Months Ended\nJune 30,\n\n\n\n\n\n\n \n\n\n\n\n\n\nDollar\nChange\n\n\n\n\n\n\n \n\n\n\n\n\n\nPercentage\nChange\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n2023\n\n\n\n\n\n\n \n\n\n\n\n\n\n2022\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTotal revenues\n\n\n\n\n\n\n$\n\n\n\n\n\n\n596.5\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n466.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n129.6\n\n\n\n\n\n\n \n\n\n\n\n\n\n28\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income\n\n\n\n\n\n\n$\n\n\n\n\n\n\n259.2\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n116.0\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n143.2\n\n\n\n\n\...